Resistance mechanisms to tyrosine kinase inhibitors in solid tumors

Publications

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Auteurs: Gonzalo Recondo, Linda Mahjoubi, Aline Maillard, Yohann Loriot, Ludovic Bigot, Francesco Facchinetti, Rastislav Bahleda, Anas Gazzah, Antoine Hollebecque, Laura Mezquita, David Planchard, Charles Naltet, Pernelle Lavaud, Ludovic Lacroix, Catherine Richon, Aurelie Abou Lovergne, Thierry De Baere, Lambros Tselikas, Olivier Deas, Claudio Nicotra, Maud Ngo-Camus, Rosa L. Frias, Eric Solary, Eric Angev
Publié dans: npj Precision Oncology, Numéro 4/1, 2020, ISSN 2397-768X
Éditeur: Nature Publishing Group
DOI: 10.1038/s41698-020-00130-7

Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Auteurs: Marine Valery, Francesco Facchinetti, David Malka, Michel Ducreux, Luc Friboulet, Antoine Hollebecque
Publié dans: Digestive and Liver Disease, Numéro 2021 Sep 20;S1590-8658(21)00770-2, 2021, ISSN 1590-8658
Éditeur: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.dld.2021.09.001

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib

Auteurs: Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C. Newton, Huiling Zhen, Luis Feliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn
Publié dans: Cancer Discovery, 2020, Page(s) CD-20-0766, ISSN 2159-8274
Éditeur: American Association for Cancer Research Inc.
DOI: 10.1158/2159-8290.cd-20-0766

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

Auteurs: Francesco Facchinetti, Ludovic Lacroix, Laura Mezquita, Jean-Yves Scoazec, Yohann Loriot, Lambros Tselikas, Anas Gazzah, Etienne Rouleau, Julien Adam, Stefan Michiels, Christophe Massard, Fabrice André, Ken A. Olaussen, Gilles Vassal, Karen Howarth, Benjamin Besse, Jean-Charles Soria, Luc Friboulet, David Planchard
Publié dans: European Journal of Cancer, Numéro 132, 2020, Page(s) 211-223, ISSN 0959-8049
Éditeur: Pergamon Press Ltd.
DOI: 10.1016/j.ejca.2020.03.025

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Auteurs: Mihaela Aldea, Lizza Hendriks, Laura Mezquita, Cécile Jovelet, David Planchard, Edouard Auclin, Jordi Remon, Karen Howarth, Jose Carlos Benitez, Anas Gazzah, Pernelle Lavaud, Charles Naltet, Ludovic Lacroix, Frank de Kievit, Clive Morris, Emma Green, Maud Ngo-Camus, Etienne Rouleau, Christophe Massard, Caroline Caramella, Luc Friboulet, Benjamin Besse
Publié dans: Journal of Thoracic Oncology, Numéro 15/3, 2020, Page(s) 383-391, ISSN 1556-0864
Éditeur: Lippincott Williams & Wilkins Ltd.
DOI: 10.1016/j.jtho.2019.11.024

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Auteurs: Diego Enrico, Ludovic Lacroix, Jeanne Chen, Etienne Rouleau, Jean-Yves Scoazec, Yohann Loriot, Lambros Tselikas, Cécile Jovelet, David Planchard, Anas Gazzah, Laura Mezquita, Maud Ngo-Camus, Stefan Michiels, Christophe Massard, Gonzalo Recondo, Francesco Facchinetti, Jordi Remon, Jean-Charles Soria, Fabrice André, Gilles Vassal, Luc Friboulet, Benjamin Besse
Publié dans: JTO Clinical and Research Reports, Numéro 1/2, 2020, Page(s) 100023, ISSN 2666-3643
Éditeur: Elsevier
DOI: 10.1016/j.jtocrr.2020.100023

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Auteurs: Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama
Publié dans: Journal of Experimental Medicine, Numéro 216/4, 2019, Page(s) 982-1000, ISSN 0022-1007
Éditeur: Rockefeller University Press
DOI: 10.1084/jem.20180870

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

Auteurs: Francesco Facchinetti, Giulio Rossi, Emilio Bria, Jean-Charles Soria, Benjamin Besse, Roberta Minari, Luc Friboulet, Marcello Tiseo
Publié dans: Cancer Treatment Reviews, Numéro 55, 2017, Page(s) 83-95, ISSN 0305-7372
Éditeur: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.ctrv.2017.02.010

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Auteurs: Laura Mezquita, Aurélie Swalduz, Cécile Jovelet, Sandra Ortiz-Cuaran, Karen Howarth, David Planchard, Virginie Avrillon, Gonzalo Recondo, Solène Marteau, Jose Carlos Benitez, Frank De Kievit, Vincent Plagnol, Ludovic Lacroix, Luc Odier, Etienne Rouleau, Pierre Fournel, Caroline Caramella, Claire Tissot, Julien Adam, Samuel Woodhouse, Claudio Nicotra, Edouard Auclin, Jordi Remon, Clive Morris, E
Publié dans: JCO Precision Oncology, Numéro 4, 2020, Page(s) 272-282, ISSN 2473-4284
Éditeur: PMC
DOI: 10.1200/po.19.00281

<p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>

Auteurs: Francesco Facchinetti, Luc Friboulet
Publié dans: Lung Cancer: Targets and Therapy, Numéro Volume 10, 2019, Page(s) 87-94, ISSN 1179-2728
Éditeur: Dove Medical Press Ltd
DOI: 10.2147/lctt.s190786

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer

Auteurs: Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Aït Oukhatar
Publié dans: Clinical Cancer Research, Numéro 26/23, 2020, Page(s) 6242-6253, ISSN 1078-0432
Éditeur: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-20-1037

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Auteurs: Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
Publié dans: Nature Reviews Clinical Oncology, 2018, ISSN 1759-4774
Éditeur: Nature Publishing Group
DOI: 10.1038/s41571-018-0081-4

Facts and new hopes on selective FGFR inhibitors in solid tumors

Auteurs: Francesco Facchinetti, Antoine Hollebecque, Rastilav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet
Publié dans: Clinical Cancer Research, 2019, Page(s) clincanres.2035.2019, ISSN 1078-0432
Éditeur: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-2035

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Auteurs: Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hol
Publié dans: Clinical Cancer Research, 2019, Page(s) clincanres.1104.2019, ISSN 1078-0432
Éditeur: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-1104

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Auteurs: Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Publié dans: Nature Communications, Numéro 12/1, 2021, ISSN 2041-1723
Éditeur: Nature Publishing Group
DOI: 10.1038/s41467-021-21396-w

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer

Auteurs: Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Laura Mezquita, Mélanie Laporte, Aurélie Honoré, Yann Lecluse, Pauline Queffelec, Maud NgoCamus, Claudio Nicotra, Jordi Remon, Ludovic Lacroix, David Planchard, Luc Friboulet, Benjamin Besse, Françoise Farace
Publié dans: Clinical Cancer Research, Numéro 25/22, 2019, Page(s) 6671-6682, ISSN 1078-0432
Éditeur: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-1176

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Auteurs: Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman
Publié dans: Cancer Discovery, Numéro 8/6, 2018, Page(s) 714-729, ISSN 2159-8274
Éditeur: American Association for Cancer Research Inc.
DOI: 10.1158/2159-8290.cd-17-1256

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

Auteurs: Francesco Facchinetti, Luc Friboulet
Publié dans: Translational Lung Cancer Research, Numéro 7/S2, 2018, Page(s) S103-S106, ISSN 2218-6751
Éditeur: AME
DOI: 10.21037/tlcr.2018.02.04

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

Auteurs: Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L
Publié dans: Annals of oncology, 2022, ISSN 0923-7534
Éditeur: Oxford University Press
DOI: 10.1016/j.annonc.2022.01.004

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC

Auteurs: Recondo, Gonzalo
Publié dans: "Cancer. Université Paris Saclay (COmUE); Universidad de Buenos Aires, 2019. English. ⟨NNT : 2019SACLS248⟩", 2019
Éditeur: Université Paris Saclay

Recherche de données OpenAIRE...

Publications

Partager cette page

Télécharger